1: Mansini AP, Peixoto E, Jin S, Richard S, Gradilone SA. The Chemosensory Function of Primary Cilia Regulates Cholangiocyte Migration, Invasion, and Tumor Growth. Hepatology. 2019 Apr;69(4):1582-1598. doi: 10.1002/hep.30308. Epub 2019 Mar 15. PubMed PMID: 30299561; PubMed Central PMCID: PMC6438749.
2: Hernandez-Pigeon H, Garidou L, Galliano MF, Delga H, Aries MF, Duplan H, Bessou-Touya S, Castex-Rizzi N. Effects of dextran sulfate, 4-t-butylcyclohexanol, pongamia oil and hesperidin methyl chalcone on inflammatory and vascular responses implicated in rosacea. Clin Cosmet Investig Dermatol. 2018 Sep 7;11:421-429. doi: 10.2147/CCID.S168621. eCollection 2018. PubMed PMID: 30233225; PubMed Central PMCID: PMC6135068.
3: Zhao Y, Jiao Y, Wang L. Hesperidin methyl chalcone alleviates spinal tuberculosis in New Zealand white rabbits by suppressing immune responses. J Spinal Cord Med. 2018 Aug 20:1-8. doi: 10.1080/10790268.2018.1507805. [Epub ahead of print] PubMed PMID: 30124375.
4: Kakkos SK, Bouskela E, Jawien A, Nicolaides AN. New data on chronic venous disease: a new place for Cyclo 3® Fort. Int Angiol. 2018 Feb;37(1):85-92. doi: 10.23736/S0392-9590.17.03935-9. Epub 2017 Oct 23. Review. PubMed PMID: 29063748.
5: Jawien A, Bouskela E, Allaert FA, Nicolaïdes AN. The place of Ruscus extract, hesperidin methyl chalcone, and vitamin C in the management of chronic venous disease. Int Angiol. 2017 Feb;36(1):31-41. doi: 10.23736/S0392-9590.16.03788-3. Review. PubMed PMID: 28124877.
6: Martinez RM, Pinho-Ribeiro FA, Steffen VS, Caviglione CV, Pala D, Baracat MM, Georgetti SR, Verri WA, Casagrande R. Topical formulation containing hesperidin methyl chalcone inhibits skin oxidative stress and inflammation induced by ultraviolet B irradiation. Photochem Photobiol Sci. 2016 Apr;15(4):554-63. doi: 10.1039/c5pp00467e. Epub 2016 Mar 29. PubMed PMID: 27021784.
7: Allaert FA. Combination of Ruscus aculeatus extract, hesperidin methyl chalcone and ascorbic acid: a comprehensive review of their pharmacological and clinical effects and of the pathophysiology of chronic venous disease. Int Angiol. 2016 Apr;35(2):111-6. Review. PubMed PMID: 26928296.
8: Martinez RM, Pinho-Ribeiro FA, Steffen VS, Caviglione CV, Vignoli JA, Baracat MM, Georgetti SR, Verri WA Jr, Casagrande R. Hesperidin methyl chalcone inhibits oxidative stress and inflammation in a mouse model of ultraviolet B irradiation-induced skin damage. J Photochem Photobiol B. 2015 Jul;148:145-153. doi: 10.1016/j.jphotobiol.2015.03.030. Epub 2015 Apr 13. PubMed PMID: 25916506.
9: Andersen KE. Hesperidin methyl chalcone - a new cosmetic contact allergen. Contact Dermatitis. 2015 Jun;72(6):402-4. doi: 10.1111/cod.12383. Epub 2015 Mar 20. PubMed PMID: 25801999.
10: Pinho-Ribeiro FA, Hohmann MS, Borghi SM, Zarpelon AC, Guazelli CF, Manchope MF, Casagrande R, Verri WA Jr. Protective effects of the flavonoid hesperidin methyl chalcone in inflammation and pain in mice: role of TRPV1, oxidative stress, cytokines and NF-κB. Chem Biol Interact. 2015 Feb 25;228:88-99. doi: 10.1016/j.cbi.2015.01.011. Epub 2015 Jan 21. PubMed PMID: 25617481.
11: Guex JJ, Avril L, Enrici E, Enriquez E, Lis C, Taïeb C. Quality of life improvement in Latin American patients suffering from chronic venous disorder using a combination of Ruscus aculeatus and hesperidin methyl-chalcone and ascorbic acid (quality study). Int Angiol. 2010 Dec;29(6):525-32. PubMed PMID: 21173734.
12: Guex JJ, Enriquez Vega DM, Avril L, Boussetta S, Taïeb C. Assessment of quality of life in Mexican patients suffering from chronic venous disorder - impact of oral Ruscus aculeatus-hesperidin-methyl-chalcone-ascorbic acid treatment - 'QUALITY Study'. Phlebology. 2009 Aug;24(4):157-65. doi: 10.1258/phleb.2009.008066. PubMed PMID: 19620698.
13: Boyle P, Diehm C, Robertson C. Meta-analysis of clinical trials of Cyclo 3 Fort in the treatment of chronic venous insufficiency. Int Angiol. 2003 Sep;22(3):250-62. PubMed PMID: 14612852.
14: Beltramino R, Penenory A, Buceta AM. An open-label, randomized multicenter study comparing the efficacy and safety of Cyclo 3 Fort versus hydroxyethyl rutoside in chronic venous lymphatic insufficiency. Angiology. 2000 Jul;51(7):535-44. PubMed PMID: 10917578.
15: Beltramino R, Penenory A, Buceta AM. An open-label, randomised multicentre study comparing the efficacy and safety of CYCLO 3 FORT versus hydroxyethyl rutoside in chronic venous lymphatic insufficiency. Int Angiol. 1999 Dec;18(4):337-42. PubMed PMID: 10811525.
16: Cluzan RV, Alliot F, Ghabboun S, Pascot M. Treatment of secondary lymphedema of the upper limb with CYCLO 3 FORT. Lymphology. 1996 Mar;29(1):29-35. PubMed PMID: 8721977.
17: Rudofsky G. [Improving venous tone and capillary sealing. Effect of a combination of Ruscus extract and hesperidine methyl chalcone in healthy probands in heat stress]. Fortschr Med. 1989 Jun 30;107(19):52, 55-8. German. PubMed PMID: 2668140.
18: Silvestri S. A thin-layer chromatographic-fluorometric method for quantitative analysis of hesperidin methyl chalcone in parmaceuticals. Pharm Acta Helv. 1970 Jun;45(6):390-1. PubMed PMID: 5426104.
19: Gábor M, Antal A, Dirner Z. Effect of hesperidin-methyl-chalcone on capillary resistance in the internal organs of the guinea pig and the rat. Acta Physiol Acad Sci Hung. 1968;34(3):221-6. PubMed PMID: 5716503.
20: DONTAS AS, CHENOWETH MB. The effect of hesperidin methyl chalcone on the nervous control of the nictitating membrane. Arch Int Pharmacodyn Ther. 1952 Sep 1;91(1-2):202-10. English, Undetermined Language. PubMed PMID: 13008500.